Jun 7 2011
KAI Pharmaceuticals, Inc., a privately held drug discovery and development company, today announced clinical and preclinical data from its lead program, KAI-4169, at the Endocrine Society's 93rd Annual Meeting (ENDO 2011) taking place in Boston, June 4-7, 2011. KAI-4169 is a novel pharmaceutical agent being developed for the treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD).
“The data available for KAI-4169 are promising, and we are excited to present at ENDO 2011”
Phase 1a pharmacokinetic and pharmacodynamic (PK/PD) data demonstrated a dose-dependent relationship between KAI-4169 exposure and reductions in serum parathyroid hormone (PTH) levels in healthy young males following single-dose administration. Further, the data validated an integrated PK/PD model that KAI believes may aid in the refinement of dose and regimen selection for future clinical studies.
Preclinical data presented at ENDO 2011 confirmed the activity of KAI-4169 as a Calcium Sensing Receptor (CaSR) agonist. The CaSR inhibits secretion of PTH from the parathyroid gland and CaSR activation by KAI-4169 resulted in dose-dependent reduction in plasma PTH levels in preclinical models of CKD-MBD. In addition, chronic dosing of KAI-4169 in an in vivo model of CKD-MBD significantly decreased vascular calcification (a major clinical complication of CKD-MBD) and reduced parathyroid gland hyperplasia.
"The data available for KAI-4169 are promising, and we are excited to present at ENDO 2011," commented Steven James, President and CEO of KAI. "We are continuing to enroll patients in our Phase 2 study of KAI-4169 and look forward to announcing further progress in this program by the end of the year."
Source KAI Pharmaceuticals
TxGNN improves drug repurposing by predicting treatments for rare diseases with no approved therapies